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Abstract
We evaluated the association of the number of late antiretroviral therapy (ART) refills with patient outcomes in a
large public-sector human immunodeficiency virus treatment program in Lusaka, Zambia. Using pharmacy data
routinely collected during 2004–2010, we calculated the number of late refills during the initial year of ART. We used
multivariable Cox proportional hazard regression to examine the association between the number of late refills and
death or program failure (i.e., death, loss to follow-up, or program withdrawal) > 12 months after ART initiation, with
and without stratification by the medication possession ratio (MPR) during the initial year of ART. Of 53,015 adults
who received ART for ‡ 12 months (median follow-up duration, 86.1 months; interquartile range, 53.2–128.2
months), 26,847 (50.6%) had 0 late refills, 16,762 (31.6%) had 1, 6,505 (12.3%) had 2, and 2,901 (5.5%) had ‡ 3. Kaplan–
Meier analysis revealed that ‡ 3 late refills was associated with a greater mortality risk than 1 and 2 late refills
( p < 0.001, by the log-rank test). The mortality risk was greater for patients with 2 late refills [adjusted hazard ratio
(HR), 1.17; 95% confidence interval (CI), 0.99–1.38] or ‡ 3 late refills (adjusted HR, 1.51; 95% CI, 1.23–1.87), compared
with that for patients with 0–1 late refills. Program failure was associated with ‡ 2 late refills. An MPR of < 80% was
associated with similar increases in mortality risk across late-refill strata. Monitoring late refills during the initial
period of ART may help resource- and time-constrained clinics identify patients at risk for program failure.
Adherence is essential to the success of antiretroviraltherapy (ART) for human immunodeficiency virus
(HIV) infection, and poor adherence to ART promotes drug
resistance, regimen failure, and ultimately death.1–4 ART ad-
herence can be measured in various ways, from self-report to
sophisticated monitoring of drug levels in samples of blood,
body fluids, and hair.3,5,6 Because of resource and time con-
straints, most ART programs in resource-limited settings rely
on self-reported adherence,3 but this metric can be inaccurate
because of recall or social-desirability bias. Alternative ad-
herence metrics that are suitable for resource-limited settings
are needed.
Pharmacy adherence measures (PAMs) can objectively esti-
mate treatment adherence, owing to their reliance on routinely
collected pharmacy data, and are predictive of ART outcomes.7–9
The medication possession ratio (MPR) is one PAM that has
become an accepted alternative to self-report.10 The MPR
measures the cumulative time that a patient has possession of
antiretroviral drugs over a given interval and has been found
to predict virologic suppression, mortality, and program fail-
ure among HIV-infected adults receiving antiretroviral ther-
apy (ART) in public health clinics in Zambia.8,11 However, the
MPR can be tedious to calculate during patient visits, partic-
ularly those involving busy, overburdened facilities, and this
undermines its usefulness as an adherence-monitoring tool.
In this study, we investigated a more practical PAM, the
number of late ART refills during the first 12 months of
treatment, as a predictor of patient outcomes. Late ART refills
may be a feasible alternative to self-report that ART programs
in resource-limited settings could use in routine adherence
monitoring. To date, this adherence metric has not been rig-
orously evaluated in field settings.
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We analyzed programmatic data from all adults (age, > 15
years) who initiated ART across 18 public-sector sites in Lu-
saka, Zambia, during 2004–2010. Details of the ART program
have been described in detail elsewhere.11,12 In brief, the
Zambian Ministry of Health has provided HIV care and ART
free of charge since April 2004. During 2004, patients were eli-
gible for ART if they had a CD4 + T cell count of < 200 cells/mm3
or World Health Organization (WHO) stage 3 or 4 disease. From
2005 to 2010, eligibility for patients with WHO stage 3 disease
also required a CD4 + T cell count of £ 350 cells/mm3. Follow-
up clinical visits and pharmacy refills occur at 2 weeks, 6
weeks, and 12 weeks after ART initiation and then every 4–12
weeks for pharmacy refills, based on facility-level factors and
presumed adherence levels, and every 12–24 weeks for clini-
cal visits, based on clinical status. CD4 + T cell count is mea-
sured every 6 months, and HIV load is measured only when
treatment failure is suspected.
We measured the number of late refills, defined as any ART
dispensation that occurred ‡ 7 days after the scheduled refill
date,13 during the first 12 months of ART. Our primary out-
comes were all-cause death and program failure, a composite
outcome composed of death, treatment cessation, and loss to
follow-up. Deaths were ascertained through family or clinic
staff report, and patients who were > 60 days late for a
scheduled appointment on the date of administrative cen-
soring were considered lost to follow-up.14 Patients who in-
terrupted treatment for > 60 days but then subsequently
returned to care were kept in the analysis. Because adherence
patterns primarily affect long-term outcomes, we excluded
patients who received ART for < 12 months from the analysis.
We stratified data by the number of late refills (0–1, 2, or
‡ 3) and compared baseline characteristics, including age, sex,
body mass index (BMI; calculated as the weight in kilograms
divided by the height in meters squared), CD4 + T cell count,
WHO disease stage, presence of tuberculosis, and ART regi-
men, using analysis of variance and v2 analysis, as appropri-
ate. We categorized continuous variables according to
previously reported cutoffs.11,12 We used multivariable lo-
gistic regression to identify the predictors of having ‡ 3 late
refills and Kaplan–Meier analysis to describe the probability
of death after month 12 of treatment. Multivariable Cox pro-
portional hazard models were used to examine the association
between the number of late refills and the primary outcomes.
Cox models were for adjusted for age, sex, BMI, CD4 + T cell
count, WHO disease stage, and ART regimen based on a
priori decision or after identification of an association with the
outcome at a p value of < 0.05 during bivariable analyses.
The proportional hazards assumption was assessed in both
the unadjusted and adjusted models using the Grambsch and
Therneau test.15
To investigate the possible interaction between the number
of late refills and the interval without ART, we stratified the
population according to MPR over the first 12 months as part
of a secondary analysis. The MPR was calculated by dividing
the number of days of ART possession (based on pharmacy
data) by 365 and multiplying the quotient by 100. MPRs were
categorized as optimal ( ‡ 95%), suboptimal (80–94%), and
poor ( < 80%) on the basis of previously established thresh-
olds.8,11 We investigated the risk of the primary outcomes,
using Cox proportional hazard models as described above.
We used SAS, version 9.1 (SAS Institute, Cary, NC), for
statistical analysis. A p value of < 0.05 was considered indic-
ative of a statistically significant difference. The ethics boards
at the University of Zambia (Lusaka) and the University of
North Carolina at Chapel Hill approved the use of program-
matic data for this study.
Between 1 April 2004 and 1 February 2010, 72,492 HIV-
infected adults initiated ART within Lusaka public-sector
clinics. Of these, 19,477 (26.9%) were excluded from analysis
because they had not been followed for at least 12 months,
owing to death [6,235 patients (8.6%)], loss to follow-up [9,937
(13.7%)], or program withdrawal [3,305 (4.6%)]. Our analysis
cohort thus consisted of the remaining 53,015 patients. Com-
pared with patients who were excluded, patients included in
analysis were more likely to be female (63% vs. 57%), had a
higher BMI (20.1 vs. 19.0), were more likely to have WHO
stage 1 or 2 disease (39% vs. 31%), had a higher CD4 + T cell
count at baseline (144 vs. 123 cells/mm3), and were more
likely to report having an adherence supporter (87% vs. 73%;
p < 0.001 for all comparisons).
In the analysis cohort, the median duration of follow-up
was 86.1 months (interquartile range, 53.2–128.2 months). A
total of 26,847 patients (50.6%) had 0 late refills, 16,762 (31.6%)
had 1, 6,505 (12.3%) had 2, and 2,901 (5.5%) had ‡ 3 (maxi-
mum of 8). Across the late-refill categories, data on age, sex,
BMI, baseline WHO disease stage, presence of tuberculosis,
and ART regimens reached statistical significance, but were
not judged to be clinically different (Supplementary Table S1;
FIG. 1. Association between the
number of late refills during the
first 12 months of antiretroviral
therapy (ART) and subsequent
mortality among 53,015 HIV-
infected Zambian adults.
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Supplementary Data are available online at www.lie
bertpub.com/aid). A greater percentage of patients with 0 late
refills had a baseline CD4 + T cell count of £ 200 cells/ll,
compared with patients with 1, 2, or ‡ 3 late refills. Patients
with 0 late refills were more likely than patients with 1 or
more late refills to report having an adherence supporter.
Baseline CD4 + T cell count was associated with the odds of
having ‡ 3 late refills in the first 12 months of ART, inde-
pendent of age, sex, BMI, WHO disease stage, ART regimen,
and report of an adherence supporter. Compared with pa-
tients with a baseline CD4 + T cell count of £ 200 cells/mm3,
patients at higher CD4 + T cell counts had increased odds of
having ‡ 3 late refills. Patients with 200–350 cells/mm3 had an
odds ratio (OR) of 1.25 [95% confidence interval (CI), 1.14–
1.36] and patients with ‡ 350 cells/mm3 had an OR of 1.47
(95% CI, 1.23–1.76).
In Kaplan–Meier analyses, patients with ‡ 3 late refills had
a higher mortality risk than patients with 2, 1, or 0 late refills
( p < 0.001, by the log-rank test; Fig. 1). The mortality risk ap-
peared to decrease as the number of late refills decreased. In
multivariable Cox models, patients with 2 late refills [adjusted
hazard ratio (HR), 1.17; 95% CI, 0.99–1.38] or ‡ 3 late refills
(adjusted HR, 1.51; 95% CI, 1.23–1.87) had an increased haz-
ard of mortality, compared with patients with 0–1 late refill.
Having ‡ 2 late refills was also associated with an increased
hazard of program failure [adjusted HR, 1.46 (95% CI, 1.39–
1.54) for 2 late refills and 1.51 (95% CI, 1.23–1.87) for ‡ 3 late
refills].
We further stratified this analysis by MPR during the first
year of ART, with patients with 0–1 late refills and an optimal
MPR constituting the reference group. Among patients with
‡ 1 late refill, the associated hazard of death and of program
failure (Table 1) increased when the MPR was poor. Com-
pared with the reference group, patients with 2 late refills and
a poor MPR had an adjusted hazard of death of 1.81 (95% CI,
1.41–2.31) and an adjusted hazard of program failure of 2.21
(95% CI, 2.04–2.39). When MPR was suboptimal, having 2 late
refills conferred a smaller but significantly increased hazard
of program failure (adjusted HR, 1.41; 95% CI, 1.32–1.50) but
was not associated with an increased hazard of death (ad-
justed HR, 1.09; 95% CI, 0.88–1.35). Similar trends in the ad-
justed hazard of program failure were seen among patients
with ‡ 3 late refills.
Among HIV-infected Zambian adults receiving ART in a
large public-sector cohort, the number of late refills during the
first 12 months of therapy was associated with risks of mor-
tality and program failure > 12 months after ART initiation.
Mortality and program failure risk doubled when MPR was
poor, regardless of the number of late ART refills.
Monitoring late refills after ART initiation could be a
widely implementable activity for measuring adherence in
resource-limited settings. In a small HIV-infected cohort in
Cameroon, late refills were better predictors of virologic fail-
ure than either CD4 + T cell count recovery or self-reported
adherence. In addition, investigators noted that unlike
other adherence measures, pharmacy data were complete in
95% of cases.9 Whereas other PAMs have been challenging
to implement in resource-limited settings because they can
be tedious to measure (in the case of pill counts) and/or
overly complex to calculate (in the case of the MPR), late re-
fills could be easily tallied in a readily observable format on
the medical chart summary page and/or on the patient’s
clinic identification card. Once a threshold of late refills is
exceeded, the patient could be referred for intensive adher-
ence interventions.
In our cohort, individuals with a poor MPR during the first
year of ART had an increased risk of mortality and program
failure independent of the number of late refills, compared
with patients with an optimal MPR and 0–1 late refills. This
suggests that although tallying the number of late refills may
offer a simple adherence measure that predicts long-term
outcomes, MPR might further enhance routine adherence
monitoring if it could be calculated in real time. Use of elec-
tronic health records in resource-limited settings could facil-
itate calculation of the MPR by documenting the cumulative
time that a patient does and does not possess ART.
Our finding that patients with higher CD4+ T cell counts
have an increased odds of having ‡ 3 late refills during the first
year of ART is concerning and requires further investigation.
Similar findings were reported in Uganda, where researchers
speculated that because relatively healthy, asymptomatic pa-
tients do not perceive that improvements in their health are
Table 1. Adjusted Hazard Ratio of Death and Program Failure During Follow-up Among 53,015
HIV-Infected Zambian Adults, by Number of Late Medication Refills and Medication Possession
Ratio During the First 12 Months of Antiretroviral Therapy, 2004–2010
Adjusted HR (95% CI), by MPRb
Outcome, no. of late
medication refillsa Optimal ( ‡ 95%) Suboptimal (80–94%) Poor ( < 80%)
Death
0–1 Reference 1.12 (0.97–1.30) 2.03 (1.63–2.52)
2 0.78 (0.11–5.58) 1.09 (0.88–1.35) 1.81 (1.41–2.31)
‡ 3 —c 1.01 (0.65–1.58) 2.07 (1.63–2.64)
Program failured
0–1 Reference 1.28 (1.22–1.35) 2.63 (2.46–2.82)
2 1.10 (0.62–1.93) 1.41 (1.32–1.50) 2.21 (2.04–2.39)
‡ 3 —c 1.57 (1.39–1.78) 2.07 (1.99–2.34)
aDefined as a pharmacy refill that took place ‡ 7 days after medication in the current dispensation was scheduled to run out.
bCalculated by dividing the number of days of ART possession (based on pharmacy data) by 365 and multiplying the quotient by 100.
cNot reported because there was only one patient in this category.
dDefined as death, loss to follow-up, or program withdrawal.
HR, hazard ratio; MPR, medication possession ratio; CI, confidence interval.
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due to ART, they may be less likely to overcome the structural,
social, and economic barriers to adherence.16 As a larger
number of individuals with high CD4 + T cell counts receive
ART under the World Health Organization’s recently revised
guidelines that include ‘‘test-and-treat’’ approaches to HIV
care,17 adherence and the consequences of poor adherence
must be closely monitored.
Several key limitations to our analysis warrant discussion.
Although PAMs are useful proxies of health behavior, they
assume that possession of a medication is highly correlated
with its ingestion. In this analysis of routine program data, we
did not have access to virologic data and were therefore un-
able to validate late refills or MPR against viral load, which is
a direct outcome of adherence. Instead we utilized a survival
outcome. Some deaths may have resulted from non-AIDS
events, but this should have had a nondifferential effect on
our results. In addition, some deaths were likely misclassified
as losses to follow-up, and for this reason we also considered
program failure as an outcome. Finally, we considered only
pharmacy refills during the first 12 months after ART initia-
tion for methodological reasons, based on the assumption that
early adherence behavior, an established predictor of long-
term ART outcomes,18 would mirror later adherence behav-
ior. A systematic difference in adherence after the first 12
months of therapy among patients in certain late-refill strata
could have implications for these findings.
In summary, among HIV-infected adults in Lusaka, Zam-
bia, the number of late refills during the first 12 months of
ART predicted the subsequent risk of death and program
failure. In each late-refill stratum, the risks were consistently
highest among patients who had a longer period without ART
(i.e., a poor MPR), suggesting that tiered approaches that in-
clude PAMs might greatly enhance clinical monitoring. While
PAMs hold great promise, continued research is needed to
understand how best to incorporate them into routine clinical
care in resource-limited settings.
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